 Denise Damek
Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 22 | 2026 | 1329 | 1.710 |
Why?
| | Glioblastoma | 12 | 2026 | 353 | 1.130 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 95 | 0.980 |
Why?
| | Astrocytoma | 5 | 2014 | 130 | 0.920 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2026 | 1149 | 0.570 |
Why?
| | Meningioma | 4 | 2022 | 88 | 0.540 |
Why?
| | Chemoradiotherapy | 5 | 2015 | 239 | 0.440 |
Why?
| | Meningeal Carcinomatosis | 2 | 2014 | 7 | 0.410 |
Why?
| | Dacarbazine | 8 | 2016 | 100 | 0.380 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2015 | 142 | 0.370 |
Why?
| | Angiogenesis Inhibitors | 2 | 2014 | 238 | 0.350 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2012 | 223 | 0.320 |
Why?
| | Glioma | 4 | 2020 | 429 | 0.320 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2016 | 74 | 0.310 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.290 |
Why?
| | Quadriplegia | 1 | 2008 | 14 | 0.290 |
Why?
| | Aspergillus | 1 | 2008 | 18 | 0.290 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.290 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 42 | 0.280 |
Why?
| | Neck | 1 | 2008 | 108 | 0.270 |
Why?
| | Brain Diseases | 1 | 2009 | 155 | 0.260 |
Why?
| | Bevacizumab | 5 | 2020 | 168 | 0.260 |
Why?
| | Posture | 1 | 2008 | 197 | 0.260 |
Why?
| | Range of Motion, Articular | 1 | 2008 | 429 | 0.240 |
Why?
| | Mutation | 3 | 2022 | 4075 | 0.230 |
Why?
| | Phenylurea Compounds | 1 | 2026 | 119 | 0.220 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1505 | 0.190 |
Why?
| | Middle Aged | 25 | 2026 | 36215 | 0.180 |
Why?
| | Pyridines | 1 | 2026 | 609 | 0.170 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 1189 | 0.170 |
Why?
| | Flucytosine | 1 | 2020 | 10 | 0.170 |
Why?
| | Cytosine Deaminase | 1 | 2020 | 15 | 0.160 |
Why?
| | Quinazolines | 3 | 2014 | 266 | 0.150 |
Why?
| | Lymphoma | 3 | 2008 | 237 | 0.150 |
Why?
| | Radiosurgery | 3 | 2010 | 399 | 0.150 |
Why?
| | Seizures | 2 | 2017 | 483 | 0.150 |
Why?
| | Multiple Sclerosis | 2 | 2012 | 489 | 0.150 |
Why?
| | Neurologic Examination | 1 | 2019 | 132 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1963 | 0.140 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2214 | 0.140 |
Why?
| | Central Nervous System Neoplasms | 3 | 2008 | 177 | 0.140 |
Why?
| | Female | 26 | 2026 | 78844 | 0.130 |
Why?
| | Brain | 2 | 2009 | 2947 | 0.130 |
Why?
| | Adenocarcinoma | 1 | 2004 | 925 | 0.130 |
Why?
| | Aged | 19 | 2026 | 26153 | 0.130 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2020 | 72 | 0.130 |
Why?
| | Humans | 34 | 2026 | 145474 | 0.130 |
Why?
| | Brain Edema | 2 | 2009 | 62 | 0.120 |
Why?
| | Magnetic Field Therapy | 1 | 2016 | 2 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2664 | 0.120 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 2381 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 992 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 202 | 0.110 |
Why?
| | Prognosis | 5 | 2015 | 4316 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 7 | 2016 | 3904 | 0.110 |
Why?
| | Survival Rate | 4 | 2015 | 2090 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2014 | 222 | 0.110 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.110 |
Why?
| | Male | 24 | 2026 | 72842 | 0.100 |
Why?
| | Combined Modality Therapy | 5 | 2016 | 1266 | 0.100 |
Why?
| | Adult | 18 | 2026 | 40777 | 0.100 |
Why?
| | Lomustine | 2 | 2026 | 17 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2930 | 0.100 |
Why?
| | Neoplasms | 1 | 2009 | 2906 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 200 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2016 | 5423 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2015 | 423 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 1997 | 602 | 0.090 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 407 | 0.080 |
Why?
| | Carcinoma | 1 | 2012 | 225 | 0.080 |
Why?
| | ErbB Receptors | 1 | 2014 | 635 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1041 | 0.070 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2009 | 14 | 0.070 |
Why?
| | Autopsy | 1 | 2009 | 94 | 0.070 |
Why?
| | Chloral Hydrate | 1 | 2008 | 3 | 0.070 |
Why?
| | Quetiapine Fumarate | 1 | 2008 | 26 | 0.070 |
Why?
| | Dibenzothiazepines | 1 | 2008 | 18 | 0.070 |
Why?
| | Piperidines | 1 | 2010 | 222 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1581 | 0.070 |
Why?
| | Oxycodone | 1 | 2008 | 52 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2012 | 534 | 0.070 |
Why?
| | Delirium | 1 | 2009 | 105 | 0.070 |
Why?
| | Prospective Studies | 7 | 2015 | 8057 | 0.070 |
Why?
| | Drug Combinations | 1 | 2008 | 396 | 0.060 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 101 | 0.060 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 128 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2008 | 211 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 337 | 0.060 |
Why?
| | Hypnotics and Sedatives | 1 | 2008 | 222 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2008 | 385 | 0.060 |
Why?
| | Acetaminophen | 1 | 2008 | 267 | 0.060 |
Why?
| | Tumor Burden | 3 | 2012 | 325 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 210 | 0.060 |
Why?
| | Occipital Lobe | 1 | 2004 | 26 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2017 | 2970 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1508 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2026 | 420 | 0.050 |
Why?
| | Drug Overdose | 1 | 2008 | 374 | 0.050 |
Why?
| | Young Adult | 4 | 2017 | 14218 | 0.050 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 14 | 0.050 |
Why?
| | Radiotherapy | 1 | 2004 | 204 | 0.050 |
Why?
| | Methotrexate | 2 | 2008 | 233 | 0.050 |
Why?
| | Time Factors | 3 | 2010 | 7123 | 0.050 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2003 | 19 | 0.050 |
Why?
| | Neurofibromin 2 | 1 | 2022 | 3 | 0.050 |
Why?
| | Neoplasm Staging | 3 | 2015 | 1471 | 0.050 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 35 | 0.050 |
Why?
| | Hydroxamic Acids | 1 | 2022 | 94 | 0.050 |
Why?
| | Karnofsky Performance Status | 2 | 2013 | 37 | 0.040 |
Why?
| | Transferases | 1 | 2022 | 27 | 0.040 |
Why?
| | Aminopyridines | 1 | 2022 | 129 | 0.040 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 782 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2022 | 17291 | 0.040 |
Why?
| | Adolescent | 4 | 2017 | 22529 | 0.040 |
Why?
| | Quality of Life | 1 | 2013 | 3204 | 0.040 |
Why?
| | Treatment Outcome | 4 | 2020 | 11772 | 0.040 |
Why?
| | Dementia | 1 | 2005 | 327 | 0.040 |
Why?
| | Survival Analysis | 2 | 2020 | 1374 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 81 | 0.040 |
Why?
| | Radiotherapy Dosage | 2 | 2010 | 288 | 0.040 |
Why?
| | Stroke | 1 | 2009 | 1270 | 0.040 |
Why?
| | Dexamethasone | 2 | 2012 | 365 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1082 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 1999 | 106 | 0.040 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1999 | 124 | 0.030 |
Why?
| | Reoperation | 2 | 2012 | 633 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1368 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 674 | 0.030 |
Why?
| | Aged, 80 and over | 5 | 2010 | 8333 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 157 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2014 | 1300 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1997 | 344 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2014 | 541 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1435 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 246 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
| | Acute Disease | 1 | 1997 | 1036 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2014 | 72 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1134 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2014 | 190 | 0.020 |
Why?
| | SEER Program | 1 | 2014 | 229 | 0.020 |
Why?
| | Exons | 1 | 2014 | 363 | 0.020 |
Why?
| | Sex Factors | 2 | 2014 | 2105 | 0.020 |
Why?
| | Proportional Hazards Models | 2 | 2010 | 1327 | 0.020 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2005 | 193 | 0.020 |
Why?
| | Chronic Disease | 1 | 1997 | 1808 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2864 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 407 | 0.020 |
Why?
| | Age Factors | 2 | 2014 | 3342 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 165 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 79 | 0.020 |
Why?
| | Carmustine | 1 | 2010 | 52 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 162 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 142 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 138 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 143 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 1997 | 2953 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2028 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3623 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 244 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 165 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 21 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 34 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2008 | 86 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 95 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1845 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 477 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 112 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 845 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 866 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 35 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 210 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 981 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3747 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 531 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 1997 | 5904 | 0.010 |
Why?
| | Dementia, Vascular | 1 | 2005 | 21 | 0.010 |
Why?
| | Optic Nerve | 1 | 2005 | 67 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1266 | 0.010 |
Why?
| | Pregnancy | 1 | 1997 | 7202 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2005 | 305 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 838 | 0.010 |
Why?
| | Lymphoma, B-Cell | 1 | 2005 | 140 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2378 | 0.010 |
Why?
| | Astrocytes | 1 | 2005 | 228 | 0.010 |
Why?
| | Microglia | 1 | 2005 | 270 | 0.010 |
Why?
| | Spinal Cord | 1 | 2005 | 382 | 0.010 |
Why?
| | Child | 1 | 2022 | 22707 | 0.010 |
Why?
| | United States | 2 | 2014 | 16098 | 0.010 |
Why?
| | Colorado | 1 | 2010 | 4553 | 0.010 |
Why?
| | Cohort Studies | 1 | 2010 | 6013 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1999 | 16 | 0.010 |
Why?
| | Remission Induction | 1 | 1999 | 307 | 0.010 |
Why?
| | Databases as Topic | 1 | 1998 | 71 | 0.010 |
Why?
| | Forecasting | 1 | 1998 | 390 | 0.010 |
Why?
| | Animals | 1 | 1997 | 38030 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 1998 | 444 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1998 | 1547 | 0.010 |
Why?
| | Hospitals | 1 | 1998 | 732 | 0.010 |
Why?
| | Logistic Models | 1 | 1998 | 2134 | 0.010 |
Why?
| | Registries | 1 | 1998 | 2406 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 6066 | 0.000 |
Why?
| | Risk Factors | 1 | 1998 | 10885 | 0.000 |
Why?
|
|
Damek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|